Biotech Values

[genisi]

Demonstrating the utility of CSF biomarkers (the other relevant pathological CSF biomarkers tested in the ADNI trial were total and phospho-tau), in the clinical setting, 37 MCI patients in the ADNI group were identified as probable to develop AD one year following a baseline CSF measurement. 33 of the 37 patients exhibited disease pathology CSF Abeta-42 and tau profiles predictive of change in disease state. The authors did state of course, that a long term followup study of the ADNI CSF biomarker signatures is necessary to validate the results as predictive AD pathology signatures.